Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review.
Venous thromboembolism (VTE) results in significant morbidity and mortality. The prevention and treatment of VTE is managed with anticoagulant therapy, historically parenteral anticoagulants such as unfractionated heparin, low molecular weight heparin, and fondaparinux, and oral vitamin K antagonists such as warfarin. In the last few years, several target-specific oral anticoagulants have been developed, including the direct thrombin inhibitor dabigatran and anti-Xa inhibitors rivaroxaban, apixaban, and edoxaban. The target-specific oral anticoagulants have proven to be noninferior to vitamin K antagonists and heparins in the prevention and treatment of VTE. This review will focus on the pharmacology, clinical trial data, and laboratory assessment of apixaban. Moreover, perioperative management, use in special populations, and management of bleeding complications in patients taking apixaban for the prevention and treatment of VTE will also be discussed.
Division of Hematology and Oncology, College of Medicine, University of Florida, Gainesville, FL, USA.
Molly W
MW
Mandernach
Division of Hematology and Oncology, College of Medicine, University of Florida, Gainesville, FL, USA ; North Florida/South Georgia Veterans Health System (NF/SGVHS), Geriatric Research, Education and Clinical Center (GRECC), Gainesville, FL, USA.
Rebecca J
RJ
Beyth
Division of Hematology and Oncology, College of Medicine, University of Florida, Gainesville, FL, USA.
Anita
A
Rajasekhar
apixaban; new oral anticoagulant; target-specific oral anticoagulant; thromboprophylaxis; venous thromboembolism